Predict your next investment

SteriGenics International company logo
Corporation
HEALTHCARE
sterigenics.com

See what CB Insights has to offer

Founded Year

1997

Stage

Series B | Alive

Total Raised

$1.5M

Last Raised

$1.5M | 26 yrs ago

About SteriGenics International

SteriGenics International is a Oak Brook, Illinois-based Healthcare company.

SteriGenics International Headquarter Location

Oak Brook, Illinois, 60523,

United States

Latest SteriGenics International News

Global Radiopharmaceuticals Market Report 2021: High Cost of Radiopharmaceuticals is Anticipated to Limit the Growth of the Market

May 24, 2021

The global radiopharmaceuticals market is expected to grow from $4.78 billion in 2020 to $5.12 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. Major players in the radiopharmaceuticals market are Siemens Healthcare Private Limited, Bayer, GE Healthcare, Novartis AG, Cardinal Health, Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A., Nordion, Inc. (A Subsidiary of Sterigenics International), Mallinckrodt plc, and Curium. The market is expected to reach $6.75 billion in 2025 at a CAGR of 7%. The high cost of radiopharmaceuticals is anticipated to limit the growth of the market. High costs and short half-life of radiopharmaceuticals are reducing their implementation in hospitals and clinics. The development cost of radiopharmaceuticals is very high compared to that of therapeutic drugs and also undergoes a very lengthy and expensive regulatory process. For instance, the cost of diagnostic radiopharmaceuticals development is $100 to $200 million for 8-10 years in comparison with the cost of pharmaceuticals, which ranges between $600 million to $1.2 billion for 10-12 years. Therefore, the high cost of radiopharmaceuticals is likely to act as a major restraint for market growth. Research collaborations and partnerships are gaining significant popularity in the radiopharmaceuticals market over recent years. Major companies operating in the radiopharmaceuticals market are collaborating with other industry players to conduct R&D activities to expand their business. For instance, in March 2020, Debiopharm, a Switzerland-based biopharmaceutical company, signed a research agreement with 3B Pharmaceuticals (3BP), a Germany-based biotechnology firm, to develop the Debio 0228 radioligand program, targeting CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. Many companies are adopting various strategic initiatives such as opening a new manufacturing facility and plant capacity expansion, which is gaining significant popularity in the radiopharmaceuticals market. For instance, in May 2019, ITM Isotopen Technologien Munchen AG (ITM) announced the launch of its new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177 containing radiopharmaceuticals. Lutetium-177 is popular under brand EndolucinBeta and is an innovative isotope used in cancer therapy. This is the company's step towards meeting the high demand for quality medical isotopes for precision oncology worldwide. In December 2019, Curium, a nuclear medicine solution provider, completed the acquisition of MAP Medical Technologies Oy, a Finnish radiopharmaceutical company, for an undisclosed amount. The acquisition is expected to expand the geographical footprint of Curium in Europe along with the product portfolio expansion. Medical Technologies Oy is a Finnish company founded in 1991 and develops and manufactures radiopharmaceuticals. The products of the company are developed to meet the needs of nuclear medicine professionals. The increasing prevalence of cancer and cardiovascular diseases is projected to drive the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a safe and effective therapeutic option over conventional medicines. Radiopharmaceuticals provide an upper hand to radiologists to treat cancer and cardiovascular diseases due to their benefits such as targeted therapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Key Topics Covered:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SteriGenics International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SteriGenics International Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.